Integral membrane protein G protein-coupled receptor
Most of theeicosanoid receptors areintegral membrane proteinG protein-coupled receptors (GPCRs) thatbind and respond toeicosanoid signaling molecules. Eicosanoids are rapidly metabolized to inactive products and therefore are short-lived. Accordingly, the eicosanoid-receptor interaction is typically limited to a local interaction: cells, upon stimulation, metabolizearachidonic acid to an eicosanoid which then binds cognate receptors on either its parent cell (acting as anautocrine signalling molecule) or on nearby cells (acting as aparacrine signalling molecule) to trigger functional responses within a restricted tissue area, e.g. an inflammatory response to an invading pathogen. In some cases, however, the synthesized eicosanoid travels through the blood (acting as ahormone-like messenger) to trigger systemic or coordinated tissue responses, e.g. prostaglandin (PG) E2 released locally travels to the hypothalamus to trigger a febrile reaction (seeFever § PGE2 release). An example of a non-GPCR receptor that binds many eicosanoids is thePPAR-γ nuclear receptor.[1]
The following is a list of human eicosanoid GPCRs grouped according to the type of eicosanoidligand that each binds:[2][3]
GPR99/OXGR1 –GPR99; GPR99, also known as the 2-oxoglutarate receptor 1 (OXGR1) or cysteinyl leukotriene receptor E (CysLTE), is a third CysLTR receptor; unlike CYSLTR1 and CYSLTR2, GPR99 binds and responds toLeukotriene E4 much more strongly than to leukotriene C4 or leukotriene D4. GPR99 is also the receptor foralpha-ketoglutarate, binding and responding to this ligand much more weakly than to any of the three cited leukotrienes. Activation of this receptor by LTC4 is associated with pro-allergic responses in cells and an animal model.[4][6] The function of GPR99 as a receptor for leukotriene E4 has been confirmed in a mouse model of allergic rhinitis.[7]
CMKLR1 –CMKLR1; CMKLR1, also termed Chemokine like receptor 1 or ChemR23, is the receptor for the eicosanoidsresolvin E1 and 18S-resolvin E2 (seespecialized pro-resolving mediators) as well as forchemerin, anadipokine protein; relative potencies in binding to and activating CMKLR1 are: resolvin E1>chemerin C-terminal peptide>18R-hydroxy-eicosapentaenoic acid (18R-EPE)>eicosapentaenoic acid (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=79). Apparently, the resolvins activate this receptor in a different manner than chemerin: resolvins act through it to suppress while chemerin acts through it to stimulate pro-inflammatory responses in target cells[12][13][14]
Oxoeicosanoid (OXE) receptor 1 –OXER1; OXER1 is the receptor for5-oxo-eicosatetraenoic acid (5-oxo-ETE) as well as certain other eicosanoids and long-chain polyunsaturated fatty acids that possess a 5-hydroxy or 5-oxo residue (see5-Hydroxyeicosatetraenoic acid); relative potencies of the latter metabolites in binding to and activating OXER1 are: 5-oxoicosatetraenoic acid>5-oxo-15-hydroxy-eioxatetraenoic acid> 5S-hydroperoxy-eicosatetraenoic acid>5-Hydroxyeicosatetraenoic acid; the 5-oxo-eicosatrienoic and 5-oxo-octadecadienoic acid analogs of 5-oxo-ETE are as potent as 5-oxo-ETE in stimulating this receptor (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=271). Activation of OXER1 is associated with pro-inflammatory and pro-allergic responses by cells and tissues as well as with the proliferation of various human cancer cell lines in culture.[16]
Prostanoids areprostaglandins (PG),thromboxanes (TX), andprostacyclins (PGI). Seven, structurally-related, prostanoid receptors fall into three categories based on the cell activation pathways and activities which they regulate. Relaxant prostanoid receptors (IP, DP1, EP2, and EP4) raise cellularcAMP levels; contractile prostanoid receptors (TP, FP, and EP1) mobilize intracellular calcium; and the inhibitory prostanoid receptor (EP3) lowers cAMP levels. A final prostanoid receptor, DP2, is structurally related to thechemotaxis class of receptors and unlike the other prostanoid receptors mediateseosinophil,basophil, andT helper cell (Th2 type) chemotactic responses. Prostanoids, particularly PGE2 and PGI2, are prominent regulators of inflammation and allergic responses as defined by studies primarily in animal models but also as suggested by studies with human tissues and, in certain cases, human subjects.[17]
DP1 (PTGDR1) –PTGDR1; DP1 is a receptor forProstaglandin D2; relative potencies in binding to and activating DP1 for the following prostanoids are: PGD2>>PGE2>PGF2α>PGI2=TXA2 (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=338). Activation of DP2 is associated with the promotion of inflammatory and the early stage of allergic responses; in limited set of circumstances, however, DP1 activation may ameliorate inflammatory responses.[18]
DP2 (PTGDR2) –PTGDR2; DP2, also termed CRTH2, is a receptor for prostaglandin D2; relative potencies in binding to and stimulating PD2 are PGD2 >>PGF2α, PGE2>PGI2=TXA2 (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339&familyId=58&familyType=GPCR). While DP1 activation causes the chemotaxis of pro-inflammatory cells such as basophils, eosinophils, and T cell lymphocytes, its deletion in mice is associated with a reduction in an acute allergic responses in a rodent model.[18] This and other observations suggest that DP2 and DP1 function to counteract each other.[19]
EP3-(PGE2) (PTGER3) –PTGER3; EP3 is a receptor for prostaglandin E2; relative potencies in binding to and stimulating EP3 are PGE2>PGF2α=PGI2>PGD2+TXA2 (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=342). Activation of EP3 is associated with the suppression of the early and late phases of allergic responses; EP3 activation is also responsible for febrile responses to inflammation.[17]
EP4-(PGE2) (PTGER4) –PTGER4; EP4 is a receptor for prostaglandin E2; relative potencies in binding to and stimulating EP4 are PGE2>PGF2α=PGI2>PGD2=TXA2 (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343). EP4, particularly in association with EP2, activation is critical for the development of arthritis in different animal models.[17]
PGF2α: FP-(PGF2α) (PTGFR) –PTGFR; FP is the receptor forprostaglandin F2 alpha; relative potencies in binding to and stimulating FP are PGF2α>PGD2>PGE2>PGI2=thromboxane A2 (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=344). This receptor is the least selective of the prostanoid receptors in that both PGD2 and PGE2 bind to and stimulate it with potencies close to that of PGF2α. FP has twosplice variants, FPa and FPb, which differ in the length of theirC-terminus tails. PGF2α-induced activation of FP has pro-inflammatory effects as well as roles in ovulation, luteolysis, contraction of uterine smooth muscle, and initiation of parturition. Analogs of PGF2α have been developed for estrus synchronization, abortion in domestic animals, influencing human reproductive function, and reducing intraocular pressure in glaucoma.[18]
PGI2 (prostacyclin): IP-(PGI2) (PTGIR) –PTGIR; IP is the receptor forprostacyclin I2; relative potencies in binding to and stimulating IP are: PGI2>>PGD2= PGE2=PGF2α>TXA2 (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=345). Activation of IP is associated with the promotion of capillary permeability in inflammation and allergic responses as well as partial suppression of experimental arthritis in animal models. IP is expressed in at least threealternatively splicedisoforms which differ in the length of their C-terminus and which also activate different cellular signaling pathways and responses.[17]
TXA2 (thromboxane): TP-(TXA2) (TBXA2R) –TBXA2R; TP is the receptor forthromboxane A2; relative potencies in binding to and stimulating TP are TXA2=PGH2>>PGD2=PGE2=PGF2α=PGI2 (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=346&familyId=58&familyType=GPCR). In addition to PGH2, severalisoprostanes have been found to be potent stimulators of and to act in part through TP.[21] The TP receptor is expressed in most human cells types as twoalternatively splicedisoforms, TP receptor-α and TP receptor β, which differ in the length of their C-terminus tail; these isoforms communicate with different G proteins, undergo heterodimerization, and thereby result in different changes in intracellular signaling (only the TP receptor α is expressed in mice). Activation of TP by TXA2 or isoprostanes is associated with pro-inflammatory responses in cells, tissues, and animal models.[18][21] TP activation is also associated with the promotion ofplatelet aggregation and therebyblood clotting andthrombosis.[22]
^DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA (1998). "The nuclear eicosanoid receptor, PPAR-γ, is aberrantly expressed in colonic cancers".Carcinogenesis.19 (1):49–53.doi:10.1093/carcin/19.1.49.PMID9472692.
^Coleman RA, Smith WL, Narumiya S (1994). "International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes".Pharmacol. Rev.46 (2):205–29.PMID7938166.
^Brink C, Dahlén SE, Drazen J, Evans JF, Hay DW, Nicosia S, Serhan CN, Shimizu T, Yokomizo T (2003). "International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors".Pharmacol. Rev.55 (1):195–227.doi:10.1124/pr.55.1.8.PMID12615958.S2CID1584172.
^Marucci G, Dal Ben D, Lambertucci C, Santinelli C, Spinaci A, Thomas A, Volpini R, Buccioni M (2016). "The G Protein-Coupled Receptor GPR17: Overview and Update".ChemMedChem.11 (23):2567–2574.doi:10.1002/cmdc.201600453.hdl:11581/394099.PMID27863043.S2CID10935349.
^Fumagalli M, Lecca D, Abbracchio MP (2016). "CNS remyelination as a novel reparative approach to neurodegenerative diseases: The roles of purinergic signaling and the P2Y-like receptor GPR17".Neuropharmacology.104:82–93.doi:10.1016/j.neuropharm.2015.10.005.hdl:2434/349470.PMID26453964.S2CID26235050.
^Brink C, Dahlén SE, Drazen J, Evans JF, Hay DW, Rovati GE, Serhan CN, Shimizu T, Yokomizo T (2004). "International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor".Pharmacol. Rev.56 (1):149–57.doi:10.1124/pr.56.1.4.PMID15001665.S2CID7229884.
